losartan has been researched along with Aldosteronism in 7 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate the effect of short-term treatment with losartan, a selective and competitive angiotensin II (AngII) receptor blocker, on vascular endothelial growth factor (VEGF), active renin and kallikrein activity (KA) in patients with essential hypertension and primary aldosteronism." | 9.09 | Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension. ( Atanassova, I; Natchev, E; Orbetzova, M; Tzingilev, D; Zacharieva, S, 2001) |
| " A total of 135 patients received captopril and losartan tests to confirm the diagnosis of PA in the TAIPAI (Taiwan Primary Aldosteronism Investigation) intervention." | 7.75 | Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests. ( Chang, HW; Chen, YM; Chiang, CK; Chueh, SC; Ho, YL; Hsieh, BS; Huang, JW; Huang, KH; Lin, WC; Lin, YH; Liu, KL; Wang, SM; Wu, KD; Wu, VC; Yang, SY, 2009) |
| "Patients with an aldosterone-producing adenoma (APA) characteristically fail to show an increase in plasma aldosterone (PA) concentration with maneuvers that increase angiotensin II (Ang II), yet they retain a brisk response of PA to adrenocorticotrophic hormone." | 7.68 | Angiotensin II receptor subtypes on adrenal adenoma in primary hyperaldosteronism. ( Cook, MD; Cook, VI; Kimura, B; Phillips, MI; Wilcox, CS, 1993) |
| "The diagnosis of primary aldosteronism (PA) among the older-aged population has posed a crucial challenge." | 5.42 | The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old. ( Balakrishnan, P; Chen, YM; Chueh, SC; Hsein, YC; Kuo, CC; Wang, MJ; Wu, KD; Wu, VC, 2015) |
| "The aim of this study was to investigate the effect of short-term treatment with losartan, a selective and competitive angiotensin II (AngII) receptor blocker, on vascular endothelial growth factor (VEGF), active renin and kallikrein activity (KA) in patients with essential hypertension and primary aldosteronism." | 5.09 | Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension. ( Atanassova, I; Natchev, E; Orbetzova, M; Tzingilev, D; Zacharieva, S, 2001) |
| " A total of 135 patients received captopril and losartan tests to confirm the diagnosis of PA in the TAIPAI (Taiwan Primary Aldosteronism Investigation) intervention." | 3.75 | Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests. ( Chang, HW; Chen, YM; Chiang, CK; Chueh, SC; Ho, YL; Hsieh, BS; Huang, JW; Huang, KH; Lin, WC; Lin, YH; Liu, KL; Wang, SM; Wu, KD; Wu, VC; Yang, SY, 2009) |
| "Patients with an aldosterone-producing adenoma (APA) characteristically fail to show an increase in plasma aldosterone (PA) concentration with maneuvers that increase angiotensin II (Ang II), yet they retain a brisk response of PA to adrenocorticotrophic hormone." | 3.68 | Angiotensin II receptor subtypes on adrenal adenoma in primary hyperaldosteronism. ( Cook, MD; Cook, VI; Kimura, B; Phillips, MI; Wilcox, CS, 1993) |
| "The diagnosis of primary aldosteronism (PA) among the older-aged population has posed a crucial challenge." | 1.42 | The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old. ( Balakrishnan, P; Chen, YM; Chueh, SC; Hsein, YC; Kuo, CC; Wang, MJ; Wu, KD; Wu, VC, 2015) |
| "Sera from 25 primary aldosteronism subjects (12 with IAH and 13 with APA) and 15 normotensive control subjects were assayed for AT1R autoantibodies by enzyme-linked immunosorbent assay and an AT1R-transfected cell-based bioassay." | 1.42 | Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism. ( Benbrook, A; Cicala, MV; Cunningham, MW; Kem, DC; Li, H; Mantero, F; Veitla, V; Yu, X, 2015) |
| "Treatment with losartan reverses this aldosterone-induced decrease in pump function, and coadministration with MR antagonists produces an additive effect on pump function, consistent with a beneficial effect of MR blockade in patients with hypertension and congestive heart failure treated with angiotensin type 1 receptor antagonists." | 1.31 | Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia. ( Funder, JW; Mardini, M; Mihailidou, AS; Raison, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kem, DC | 2 |
| Li, H | 2 |
| Velarde-Miranda, C | 1 |
| Liles, C | 1 |
| Vanderlinde-Wood, M | 1 |
| Galloway, A | 1 |
| Khan, M | 1 |
| Zillner, C | 1 |
| Benbrook, A | 2 |
| Rao, V | 1 |
| Gomez-Sanchez, CE | 1 |
| Cunningham, MW | 2 |
| Yu, X | 2 |
| Kuo, CC | 1 |
| Balakrishnan, P | 1 |
| Hsein, YC | 1 |
| Wu, VC | 2 |
| Chueh, SC | 2 |
| Chen, YM | 2 |
| Wu, KD | 2 |
| Wang, MJ | 1 |
| Cicala, MV | 1 |
| Mantero, F | 1 |
| Veitla, V | 1 |
| Chang, HW | 1 |
| Liu, KL | 1 |
| Lin, YH | 1 |
| Lin, WC | 1 |
| Ho, YL | 1 |
| Huang, JW | 1 |
| Chiang, CK | 1 |
| Yang, SY | 1 |
| Wang, SM | 1 |
| Huang, KH | 1 |
| Hsieh, BS | 1 |
| Mihailidou, AS | 1 |
| Mardini, M | 1 |
| Funder, JW | 1 |
| Raison, M | 1 |
| Cook, MD | 1 |
| Phillips, MI | 1 |
| Cook, VI | 1 |
| Kimura, B | 1 |
| Wilcox, CS | 1 |
| Zacharieva, S | 1 |
| Atanassova, I | 1 |
| Natchev, E | 1 |
| Orbetzova, M | 1 |
| Tzingilev, D | 1 |
1 trial available for losartan and Aldosteronism
| Article | Year |
|---|---|
Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Topics: Administration, Oral; Age Factors; Aldosterone; Angiotensin Receptor Antagonists; Antihypertensive A | 2001 |
6 other studies available for losartan and Aldosteronism
| Article | Year |
|---|---|
Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Autoantibodies; Autoimmun | 2014 |
The value of losartan suppression test in the confirmatory diagnosis of primary aldosteronism in patients over 50 years old.
Topics: Aldosterone; Captopril; Demography; Female; Humans; Hyperaldosteronism; Hypertension; Losartan; Male | 2015 |
Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Autoantibodies; Enzyme-Linked Immunosorbent As | 2015 |
Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Area Under | 2009 |
Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Eplerenone; Heart Ventricles | 2002 |
Angiotensin II receptor subtypes on adrenal adenoma in primary hyperaldosteronism.
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angioten | 1993 |